Neogap fully takes over TCER Oncology shares

Neogap Therapeutics A/B was joined by new shareholders Prof.  Rolf Kiessling and his team member Stina Wickström who took over the remaining 30% in shares owned  by Neogap’s subsidiary TCER Oncology. Previously, the holders of a patent application have investigated how Neogap’s EpiTCer^® beads can be used to to pulse neoantigens onto dendritic cells (DCs) and activate tumour-specific CD8⁺-T cells to infiltrate solid tumours.

In May, Neogap Therapeutics and Swiss multiple sclerosis specialist Cellerys have entered into a collaboration und which Cellerys will use Neogap’s patented EpiTCer technology in its upcoming Phase II study of a new type of cell therapy aimed at inducing antigen-specific immune tolerance in patients with multiple sclerosis (MS).

The acquisition of TCER Oncology extends  Neogap’s patent portfolio and drug pipeline, because the autologous DCs pulsed with bioinformatically deduced tumour neoantigens can be either used as autologous cancer vaccines or to enrich for tumor-specific CD8⁺ T cells from peripheral lymphocytes.

“We are delighted to acquire the remaining shares in TCER Oncology and extend a warm welcome to Rolf Kiessling and Stina Wickström as valued shareholders in Neogap. This acquisition marks an important milestone, fortifying our standing in personalised immunotherapy. It allows us to expand our patent portfolio and pipeline of potential drug candidates while further developing our innovations in the field. We look forward to continuing to drive progress and deliver groundbreaking scientific breakthroughs in cancer treatment,” said Samuel Svensson, CEO of Neogap.